Regeneron Pharmaceuticals said the Food and Drug Administration has approved Livsayis as a treatment for certain adult patients suffering from generalized myasthenia gravis.
The condition is an autoimmune muscular disorder which can result in weakened muscles, trouble breathing, and altered vision, among other symptoms. The Myasthenia Gravis Foundation of America said a 2021 study estimated that 37 out of every 100,000 people in the U.S. have myasthenia gravis.
Livsayis, or cemdisiran, is a small interfering RNA therapeutic that reduces levels of circulating C5 protein, limiting terminal complement activation, a key driver of the disease, the company said. Regeneron added Livsayis is its first approved siRNA therapy and neurology medicine.
Livsayis is the first and only approved siRNA therapy in generalized myasthenia gravis and the only FDA-approved treatment for the condition administered subcutaneously four times a year, according to Regeneron.
Comments